Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

12

US Previously Marketed

2

Other

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

HMG-CoA reductase

14

3-hydroxy-3-methylglutaryl-coenzyme A reductase

6

Cytochrome P450 3A4

6

Solute carrier organic anion transporter family member 1B1

6

Solute carrier organic anion transporter family member 3A1

6

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

12

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1991

6

2003

6

1997

2

Unknown

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Hypercholesterolemia

8

Atherosclerosis

6

Coronary heart disease mortality and cardiovascular events

6

Dysbetalipoproteinemia

6

Dyslipidemia

6

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

14

Preventing

6

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Non-penetrant

8

CNS Penetrant

6

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Merck

6

Shionogi

6

Bayer

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

15

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

15

FDA UNII

15

PUBCHEM

15

EPA CompTox

11

SMS_ID

10

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

CARDIOVASCULAR SYSTEM

3

ALIMENTARY TRACT AND METABOLISM

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

LIPID MODIFYING AGENTS

3

DRUGS USED IN DIABETES

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

LIPID MODIFYING AGENTS, PLAIN

3

BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS

2

LIPID MODIFYING AGENTS, COMBINATIONS

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

HMG CoA reductase inhibitors

3

Dipeptidyl peptidase 4 (DPP-4) inhibitors

2

HMG CoA reductase inhibitors in combination with other lipid modifying agents

2

HMG CoA reductase inhibitors, other combinations

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

11

Principal Form

4

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 10 of 15 results

First page disabled
Previous page disabled
1
Next page
Next page

Rosuvastatin

413KH5ZJ73

Export Data
Search for Structure

Status:

US Approved Rx (2016)

First approved in 2003

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

HMG-CoA reductase

Conditions:

Hypertriglyceridemia

Dysbetalipoproteinemia

Hypercholesterolemia

Atherosclerosis

CRESTOR (rosuvastatin calcium) is an inhibitor of HMG-CoA reductase. It has been widely launched for the treatment of patients with dyslipidaemia and has also been approved in the US and EU to slow the progression of atherosclerosis.

TENIVASTATIN

9L6M5TH46B

Export Data
Search for Structure

Status:

US Approved Rx (2016)

First approved in 1991

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Solute carrier organic anion transporter family member 3A1

Solute carrier organic anion transporter family member 1B1

3-hydroxy-3-methylglutaryl-coenzyme A reductase

Cytochrome P450 3A4

HMG-CoA reductase

Conditions:

Coronary heart disease mortality and cardiovascular events

Homozygous and heterozygous familial hypercholesterolemia

Simvastatin is a HMG-CoA Reductase Inhibitor that is FDA approved for the treatment of hypercholesterolemia and for the reduction in the risk of cardiac heart disease mortality and cardiovascular events. It reduces levels of "bad" cholesterol (low-de...

nsity lipoprotein, or LDL) and triglycerides in the blood, while increasing levels of "good" cholesterol (high-density lipoprotein, or HDL). Common adverse reactions include abdominal pain, constipation, nausea, headache, upper respiratory infection. Cases of myopathy/rhabdomyolysis have been observed with simvastatin co-administered with lipid-modifying doses ( ≥ 1 g/day niacin) of niacin-containing products. The risk of myopathy, including rhabdomyolysis, is increased by concomitant administration of amiodarone, dronedarone, ranolazine, or calcium channel blockers such as verapamil, diltiazem, or amlodipine.

STATINE

YTC77XR1EK

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ABSOLUTE)

CERIVASTATIN SODIUM

6Q18G1060S

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1997

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

HMG-CoA reductase

Conditions:

Hypercholesterolemia

Mixed dyslipidemia (Fredrickson types IIa and IIb)

Cerivastatin (BAYCOL®) is a competitive inhibitor of HMG-CoA reductase, which is responsible for the conversion of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) to mevalonate, a precursor of sterols, including cholesterol. The inhibition of choles...

terol biosynthesis by cerivastatin reduces the level of cholesterol in hepatic cells, which stimulates the synthesis of low-density lipoprotein (LDL) receptors, thereby increasing the uptake of cellular LDL particles. The end result of these biochemical processes is a reduction of the plasma cholesterol concentration. On August 8, 2001 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew BAYCOL® from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Canadian market.

Rosuvastatin Sodium

WFE698V54G

Export Data
Search for Structure

Status:

US Approved Rx (2016)

First approved in 2003

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

HMG-CoA reductase

Conditions:

Hypertriglyceridemia

Dysbetalipoproteinemia

Hypercholesterolemia

Atherosclerosis

CRESTOR (rosuvastatin calcium) is an inhibitor of HMG-CoA reductase. It has been widely launched for the treatment of patients with dyslipidaemia and has also been approved in the US and EU to slow the progression of atherosclerosis.

tert-Butylazanium;(E,3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate

D4M5V2K6E9

Export Data
Search for Structure

Status:

US Approved Rx (2016)

First approved in 2003

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

HMG-CoA reductase

Conditions:

Hypertriglyceridemia

Dysbetalipoproteinemia

Hypercholesterolemia

Atherosclerosis

CRESTOR (rosuvastatin calcium) is an inhibitor of HMG-CoA reductase. It has been widely launched for the treatment of patients with dyslipidaemia and has also been approved in the US and EU to slow the progression of atherosclerosis.

ROSUVASTATIN DIASTEREOMERS

K637T66PWQ

Export Data
Search for Structure

Status:

US Approved Rx (2016)

First approved in 2003

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

HMG-CoA reductase

Conditions:

Hypertriglyceridemia

Dysbetalipoproteinemia

Hypercholesterolemia

Atherosclerosis

CRESTOR (rosuvastatin calcium) is an inhibitor of HMG-CoA reductase. It has been widely launched for the treatment of patients with dyslipidaemia and has also been approved in the US and EU to slow the progression of atherosclerosis.

ROSUVASTATIN ZINC

70VE4E19Z7

Export Data
Search for Structure

Status:

US Approved Rx (2016)

First approved in 2003

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

HMG-CoA reductase

Conditions:

Hypertriglyceridemia

Dysbetalipoproteinemia

Hypercholesterolemia

Atherosclerosis

CRESTOR (rosuvastatin calcium) is an inhibitor of HMG-CoA reductase. It has been widely launched for the treatment of patients with dyslipidaemia and has also been approved in the US and EU to slow the progression of atherosclerosis.

Rosuvastatin calcium

83MVU38M7Q

Export Data
Search for Structure

Status:

US Approved Rx (2016)

First approved in 2003

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

HMG-CoA reductase

Conditions:

Hypertriglyceridemia

Dysbetalipoproteinemia

Hypercholesterolemia

Atherosclerosis

CRESTOR (rosuvastatin calcium) is an inhibitor of HMG-CoA reductase. It has been widely launched for the treatment of patients with dyslipidaemia and has also been approved in the US and EU to slow the progression of atherosclerosis.

SIMVASTATIN

AGG2FN16EV

Export Data
Search for Structure

Status:

US Approved Rx (2016)

First approved in 1991

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Solute carrier organic anion transporter family member 3A1

Solute carrier organic anion transporter family member 1B1

3-hydroxy-3-methylglutaryl-coenzyme A reductase

Cytochrome P450 3A4

HMG-CoA reductase

Conditions:

Coronary heart disease mortality and cardiovascular events

Homozygous and heterozygous familial hypercholesterolemia

Simvastatin is a HMG-CoA Reductase Inhibitor that is FDA approved for the treatment of hypercholesterolemia and for the reduction in the risk of cardiac heart disease mortality and cardiovascular events. It reduces levels of "bad" cholesterol (low-de...

nsity lipoprotein, or LDL) and triglycerides in the blood, while increasing levels of "good" cholesterol (high-density lipoprotein, or HDL). Common adverse reactions include abdominal pain, constipation, nausea, headache, upper respiratory infection. Cases of myopathy/rhabdomyolysis have been observed with simvastatin co-administered with lipid-modifying doses ( ≥ 1 g/day niacin) of niacin-containing products. The risk of myopathy, including rhabdomyolysis, is increased by concomitant administration of amiodarone, dronedarone, ranolazine, or calcium channel blockers such as verapamil, diltiazem, or amlodipine.

Showing 1 - 10 of 15 results

First page disabled
Previous page disabled
1
Next page
Next page

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1